Treatment strategy for hypopharyngeal cancer: From the viewpoint of the radiation oncologist

Katsumasa Nakamura, Yoshiyuki Shioyama, Satoru Nomoto, Ohga Saiji, Takashi Toba, Tadamasa Yoshitake, Hiroshi Honda, Shizuo Komune, Torahiko Nakashima, Yuichiro Kuratomi

研究成果: ジャーナルへの寄稿記事

抄録

Chemoradiotherapy plays an important role in the treatment of hypopharyngeal cancer. At Kyushu University, patients with hypopharyngeal cancer are initially treated with 30-40 Gy of irradiation with chemotherapy. The patients who demonstrate a good response continue to receive further radiotherapy. The other patients with poor response to radiotherapy receive surgery. In 44 patients with stage I-II hypopharyngeal cancer, 32 patients received chemoradiotherapy and 11 patients received surgery. There were no significant differences in 5-year disease-specific survival rates between the two groups (88.4% vs 90.9%). Local control with laryngeal voice preservation was achieved in 8 (88.9%) of 9 patients with stage I disease, and in 23 (67.6%) of 34 patients with stage II disease. In 175 patients with stage III-IV hypopharyngeal cancer, 90 patients were treated with chemotherapy, and 85 patients were treated by surgery after preoperative chemoradiotherapy. There were no significant differences in 5-year disease-specific survival rates between the two groups. However, 5-year local recurrence-free survival rates in radiotherapy group was 90.9% in T1, 59.7% in T2, 46.0% in T3, and 34.9% in T4. Patients with radiosensitive hypopharyngeal cancer seem to be curable with chemoradiotherapy, although local control rates should be improved.

元の言語英語
ページ(範囲)305-308
ページ数4
ジャーナルToukeibu Gan
33
発行部数3
DOI
出版物ステータス出版済み - 1 1 2007

Fingerprint

Hypopharyngeal Neoplasms
Chemoradiotherapy
Therapeutics
Radiotherapy
Survival Rate
Radiation Oncologists
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology
  • Oncology

これを引用

Treatment strategy for hypopharyngeal cancer : From the viewpoint of the radiation oncologist. / Nakamura, Katsumasa; Shioyama, Yoshiyuki; Nomoto, Satoru; Saiji, Ohga; Toba, Takashi; Yoshitake, Tadamasa; Honda, Hiroshi; Komune, Shizuo; Nakashima, Torahiko; Kuratomi, Yuichiro.

:: Toukeibu Gan, 巻 33, 番号 3, 01.01.2007, p. 305-308.

研究成果: ジャーナルへの寄稿記事

Nakamura, K, Shioyama, Y, Nomoto, S, Saiji, O, Toba, T, Yoshitake, T, Honda, H, Komune, S, Nakashima, T & Kuratomi, Y 2007, 'Treatment strategy for hypopharyngeal cancer: From the viewpoint of the radiation oncologist', Toukeibu Gan, 巻. 33, 番号 3, pp. 305-308. https://doi.org/10.5981/jjhnc.33.305
Nakamura, Katsumasa ; Shioyama, Yoshiyuki ; Nomoto, Satoru ; Saiji, Ohga ; Toba, Takashi ; Yoshitake, Tadamasa ; Honda, Hiroshi ; Komune, Shizuo ; Nakashima, Torahiko ; Kuratomi, Yuichiro. / Treatment strategy for hypopharyngeal cancer : From the viewpoint of the radiation oncologist. :: Toukeibu Gan. 2007 ; 巻 33, 番号 3. pp. 305-308.
@article{e764aa8f72424fa39952529f7921ec4c,
title = "Treatment strategy for hypopharyngeal cancer: From the viewpoint of the radiation oncologist",
abstract = "Chemoradiotherapy plays an important role in the treatment of hypopharyngeal cancer. At Kyushu University, patients with hypopharyngeal cancer are initially treated with 30-40 Gy of irradiation with chemotherapy. The patients who demonstrate a good response continue to receive further radiotherapy. The other patients with poor response to radiotherapy receive surgery. In 44 patients with stage I-II hypopharyngeal cancer, 32 patients received chemoradiotherapy and 11 patients received surgery. There were no significant differences in 5-year disease-specific survival rates between the two groups (88.4{\%} vs 90.9{\%}). Local control with laryngeal voice preservation was achieved in 8 (88.9{\%}) of 9 patients with stage I disease, and in 23 (67.6{\%}) of 34 patients with stage II disease. In 175 patients with stage III-IV hypopharyngeal cancer, 90 patients were treated with chemotherapy, and 85 patients were treated by surgery after preoperative chemoradiotherapy. There were no significant differences in 5-year disease-specific survival rates between the two groups. However, 5-year local recurrence-free survival rates in radiotherapy group was 90.9{\%} in T1, 59.7{\%} in T2, 46.0{\%} in T3, and 34.9{\%} in T4. Patients with radiosensitive hypopharyngeal cancer seem to be curable with chemoradiotherapy, although local control rates should be improved.",
author = "Katsumasa Nakamura and Yoshiyuki Shioyama and Satoru Nomoto and Ohga Saiji and Takashi Toba and Tadamasa Yoshitake and Hiroshi Honda and Shizuo Komune and Torahiko Nakashima and Yuichiro Kuratomi",
year = "2007",
month = "1",
day = "1",
doi = "10.5981/jjhnc.33.305",
language = "English",
volume = "33",
pages = "305--308",
journal = "Japanese Journal of Head and Neck Cancer",
issn = "1349-5747",
publisher = "Nihon Tokeibu Gan Gakkai",
number = "3",

}

TY - JOUR

T1 - Treatment strategy for hypopharyngeal cancer

T2 - From the viewpoint of the radiation oncologist

AU - Nakamura, Katsumasa

AU - Shioyama, Yoshiyuki

AU - Nomoto, Satoru

AU - Saiji, Ohga

AU - Toba, Takashi

AU - Yoshitake, Tadamasa

AU - Honda, Hiroshi

AU - Komune, Shizuo

AU - Nakashima, Torahiko

AU - Kuratomi, Yuichiro

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Chemoradiotherapy plays an important role in the treatment of hypopharyngeal cancer. At Kyushu University, patients with hypopharyngeal cancer are initially treated with 30-40 Gy of irradiation with chemotherapy. The patients who demonstrate a good response continue to receive further radiotherapy. The other patients with poor response to radiotherapy receive surgery. In 44 patients with stage I-II hypopharyngeal cancer, 32 patients received chemoradiotherapy and 11 patients received surgery. There were no significant differences in 5-year disease-specific survival rates between the two groups (88.4% vs 90.9%). Local control with laryngeal voice preservation was achieved in 8 (88.9%) of 9 patients with stage I disease, and in 23 (67.6%) of 34 patients with stage II disease. In 175 patients with stage III-IV hypopharyngeal cancer, 90 patients were treated with chemotherapy, and 85 patients were treated by surgery after preoperative chemoradiotherapy. There were no significant differences in 5-year disease-specific survival rates between the two groups. However, 5-year local recurrence-free survival rates in radiotherapy group was 90.9% in T1, 59.7% in T2, 46.0% in T3, and 34.9% in T4. Patients with radiosensitive hypopharyngeal cancer seem to be curable with chemoradiotherapy, although local control rates should be improved.

AB - Chemoradiotherapy plays an important role in the treatment of hypopharyngeal cancer. At Kyushu University, patients with hypopharyngeal cancer are initially treated with 30-40 Gy of irradiation with chemotherapy. The patients who demonstrate a good response continue to receive further radiotherapy. The other patients with poor response to radiotherapy receive surgery. In 44 patients with stage I-II hypopharyngeal cancer, 32 patients received chemoradiotherapy and 11 patients received surgery. There were no significant differences in 5-year disease-specific survival rates between the two groups (88.4% vs 90.9%). Local control with laryngeal voice preservation was achieved in 8 (88.9%) of 9 patients with stage I disease, and in 23 (67.6%) of 34 patients with stage II disease. In 175 patients with stage III-IV hypopharyngeal cancer, 90 patients were treated with chemotherapy, and 85 patients were treated by surgery after preoperative chemoradiotherapy. There were no significant differences in 5-year disease-specific survival rates between the two groups. However, 5-year local recurrence-free survival rates in radiotherapy group was 90.9% in T1, 59.7% in T2, 46.0% in T3, and 34.9% in T4. Patients with radiosensitive hypopharyngeal cancer seem to be curable with chemoradiotherapy, although local control rates should be improved.

UR - http://www.scopus.com/inward/record.url?scp=85009628185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009628185&partnerID=8YFLogxK

U2 - 10.5981/jjhnc.33.305

DO - 10.5981/jjhnc.33.305

M3 - Article

AN - SCOPUS:85009628185

VL - 33

SP - 305

EP - 308

JO - Japanese Journal of Head and Neck Cancer

JF - Japanese Journal of Head and Neck Cancer

SN - 1349-5747

IS - 3

ER -